Vaccinex implements 1-for-14 reverse stock split to regain Nasdaq minimum bid price compliance

VACCINEX, INC.

Split effective 5:00 p.m. ET Feb 19, 2024; shares trade split-adjusted from Feb 20.
Ratio 1-for-14, approved by board and stockholders; new CUSIP 918640301.
Complying with $1.00 minimum bid price required by Nasdaq by March 4, 2024.
Fractional shares rounded up; authorized shares unchanged; equity awards adjusted.
Shares continue trading under symbol VCNX; transfer agent is Computershare.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

VACCINEX, INC.: Implemented a 1-for-14 reverse stock split of the Company's issued common stock, effective at 5:00 p.m. Eastern Time on February 19, 2024, via a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-02-19).

Change: charter amendment
Effective: 2024-02-19

Exact text from the filing

On February 14, 2024, Vaccinex, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended, with the Delaware Secretary of State to implement a reverse stock split of the Company’s issued shares of common stock at a ratio of 1-for-14, effective at 5:00 p.m. Eastern Time on Monday February 19, 2024 (the “Reverse Stock Split”), previously approved by the Company’s Board of Directors.

View on SEC.gov

235 governance changes filed in the last 30 days. Browse all governance changes →

VACCINEX, INC. filing history →

Source: SEC EDGAR

accession 0001193125-24-037078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.